With an eye on treatment
we are dedicated to addressing patient needs with lasting impact.
DEXYCU is approved for the treatment of inflammation following ocular surgery.
By 2030, ~6 million cataract surgeries a year will be performed in the US
We created simplified treatment
Cataract surgeries will continue to grow as the population ages.
Rights for China, Hong Kong, Taiwan, Macau , Korea, and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint.